Brennan Daniel J.'s Form 4 filing
Boston Scientific Corp (BSX) · filed Feb 17, 2022
- Accession no.
- 0001225208-22-002658
- Filed
- Feb 17, 2022
- Trade date
- Feb 15-16, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $929.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brennan Daniel J.CIK 0001595612 | Officer (EVP and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2022 | Common Stock | MOption exerciseAcquired | +4,153 | $0.00F1 | $0 | 276,532 | Direct | |
| Feb 15, 2022 | Common Stock | FTax withholdingDisposed | −1,219 | $44.01 | −$53,648.19 | 275,313 | Direct | |
| Feb 15, 2022 | Common Stock | SSaleDisposed | −9,136 | $43.47F3 | −$397,141.92 | 266,177 | Direct | |
| Feb 16, 2022 | Common Stock | MOption exerciseAcquired | +12,187 | $6.28 | +$76,534.36 | 278,364 | Direct | |
| Feb 16, 2022 | Common Stock | SSaleDisposed | −12,187 | $43.70F4 | −$532,571.9 | 266,177 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2022 | Common Stock | MOption exerciseDisposed | −4,153 | $0.00 | $0 | 4,153 | Direct | |
| Feb 16, 2022 | Common Stock | AGrant or awardAcquired | +16,972 | $0.00 | $0 | 16,972 | Direct | |
| Feb 16, 2022 | Common Stock | AGrant or awardAcquired | +48,529 | $0.00 | $0 | 48,529 | Direct | |
| Feb 16, 2022 | Common Stock | MOption exerciseDisposed | −12,187 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.32 to $43.62, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.84, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
brennanpoa.txt